Promising combo for brain metastases in HER2+ breast cancer falls short
NCT ID NCT07166367
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tested a combination of two drugs, ASLAN001 and capecitabine, in patients with HER2-positive breast cancer that had spread to the brain and continued to grow despite radiation. The study aimed to see if the treatment could shrink brain tumors. However, the trial was terminated early after enrolling only 3 participants, so no firm conclusions can be drawn about its effectiveness or safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ASLAN001 (varlitinib) plus capecitabine (Xeloda)
- What this could lead to
- If it works, this could offer a new treatment option for HER2-positive breast cancer patients whose brain tumors continue to grow after radiation therapy.
- What could go wrong
- This trial was terminated early with only 3 participants, so results are very limited. It is unclear if the combination is effective or safe for this specific condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Centre Singapore
Singapore, 169610, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?